Literature DB >> 2871220

Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.

P Dorow, W Schiess.   

Abstract

Twelve subjects with chronic obstructive lung disease and a partially reversible obstruction received increasing single doses of bopindolol (1, 2, 4, and 8 mg), pindolol (7.5, 15, and 30 mg), and atenolol (50 and 100 mg). Resting heart rate and blood pressure were reduced in a dose-dependent fashion. The actions of the drugs on lung function were assessed by whole body plethysmography. Pindolol did not influence mean airway resistance (Raw). Bopindolol (1, 2 and 4 mg) and atenolol (50 mg) exhibited a neutral effect on mean Raw. Atenolol (100 mg) and to a lesser extent bopindolol (8 mg) induced a long-lasting increase in mean Raw.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2871220     DOI: 10.1007/bf01728185

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  8 in total

1.  The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics.

Authors:  H Formgren
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

2.  Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.

Authors:  W Schiess; D Welzel; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Influence of labetalol, propranolol and practolol in patients with asthma.

Authors:  A S Kochar; R Barman
Journal:  Eur J Respir Dis       Date:  1982-11

4.  Drugs and the heart.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

5.  Influence of intrinsic sympathomimetic activity (ISA) during beta-adrenoceptor blockade in asthmatics.

Authors:  P Dorow
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Assessment of beta-adrenoceptor antagonists in asthmatic patients.

Authors:  R E Ruffin; E L McIntyre; K M Latimer; H E Ward; A J Crockett; J H Alpers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

7.  Simultaneous modeling of bopindolol kinetics and dynamics.

Authors:  R Platzer; R L Galeazzi; W Niederberger; J Rosenthaler
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

8.  Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age.

Authors:  U L Hulthén; P van Brummelen; F W Amann; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

  8 in total
  1 in total

Review 1.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.